TICKERNERD
Menu
INOINOHealthcare · Biotechnology

INO Stock Forecast: Inovio Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.25
−2.34% on the day

The 3 Wall Street analysts covering Inovio Pharmaceuticals, Inc. hold a median 12-month price target of $3 — +140.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$129.2M
Ticker Nerd rank
42 / 100
Median analyst target
$3.00
Analysts covering
3
Revenue$0.0−100.0% y/y
Operating income−$21.9M
Net income−$19.7M
Free cash flow−$21.6M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.1%
1M
+62.3%
YTD
−28.2%
1Y
−52.8%
From 52W high
−52.8%
From 52W low
+89.4%
$0.66
$2.65
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Inovio Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
73
Revisions
68
Accruals
58
Growth
56
Issuance
52
Value
38
Volatility
37
Momentum
28
Quality
16

Size (73): Smaller than most of the companies we track.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26INOHigh $4.00Median $3.00Low $2.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $2.50Median $3.00High $4.00

The green dot is the last close — the median target sits +140.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
13 Aug 2026JefferiesUpgradeBuy$1.80 → $3.00
3 Aug 2026Piper SandlerReiteratesOverweight$6.00 → $4.00
3 Aug 2026Piper SandlerReiteratesOverweight—
1 June 2026HC Wainwright & Co.MaintainsNeutral$3.00 → $2.50
1 June 2026HC Wainwright & Co.MaintainsNeutral—
14 Nov 2025Piper SandlerReiteratesOverweight—
14 Aug 2025HC Wainwright & Co.ReiteratesNeutral—
9 July 2025Piper SandlerInitiatesOverweight—
14 May 2025OppenheimerMaintainsOutperform—
14 May 2025RBC CapitalReiteratesSector Perform—
19 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
19 Mar 2025RBC CapitalMaintainsSector Perform—
14 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform$18
13 Jan 2025HC Wainwright & Co.MaintainsNeutral—
10 Jan 2025JMP SecuritiesReiteratesMarket Outperform—
18 Nov 2024HC Wainwright & Co.MaintainsNeutral—
18 Nov 2024OppenheimerMaintainsOutperform—
15 Nov 2024RBC CapitalMaintainsSector Perform—
4 Oct 2024RBC CapitalMaintainsSector Perform$8.00 → $7.00
12 Aug 2024OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Inovio Pharmaceuticals, Inc. returned −52.8% against +17.5% for the S&P 500, dividends included.

INO vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26INOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Inovio Pharmaceuticals, Inc. (INO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
1978.0×

Cheaper than 1% of US stocks

Price / book
23.6×

Cheaper than 4% of US stocks

EV / EBITDA
−1.3×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−130000.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−409.9%

Higher than 4% of US stocks

Return on assets
−84.2%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Inovio Pharmaceuticals, Inc. (INO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Inovio Pharmaceuticals, Inc. has a market value of $129.2M and an enterprise value of $100.6M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$84.9M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$83.6M, after $226K of capital spending.

  • Shares outstanding: 103.4M.

  • Trailing P/E: −0.7×; forward P/E: −2.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Inovio Pharmaceuticals, Inc. employs 112 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

INO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INOInovio Pharmaceuticals, Inc.$129.2M
42
NAUTNautilus Biotechnology, Inc.$129.6M
52
CNTBConnect Biopharma Holdings Ltd.$128.4M
25
VTVTvTv Therapeutics, Inc.$125.9M
77
OKUROnKure Therapeutics, Inc.$125.2M
52
EQEquillium, Inc.$133.4M
43
HURATuHURA Biosciences, Inc.$124.5M
19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Inovio Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INO news & analysis

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Seeking Alpha · 11 Sept 2026neutral

Inovio Pharmaceuticals presented prepared remarks at the H.C. Wainwright 28th Annual Global Investment Conference. A transcript of these remarks has been published on Seeking Alpha.

Why it matters — The prepared remarks offer INO watchers a direct account of what the company communicated to investors at a major industry conference.

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

MarketBeat · 11 Sept 2026neutral

Inovio Pharmaceuticals announced that its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, remains under FDA review with a target action date of Oct. 30.

Why it matters — The upcoming PDUFA date is a key regulatory milestone for INO-3107, and its FDA decision could significantly affect Inovio's outlook.

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

MarketBeat · 10 Sept 2026neutral

Inovio Pharmaceuticals is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis (RRP), as disclosed by President and CEO Jacky Shea during a Cantor Fitzgerald fireside chat.

Why it matters — The upcoming FDA decision date for INO-3107 marks a key regulatory milestone for Inovio's lead candidate in RRP.

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha · 9 Sept 2026neutral

The news item reports that Inovio Pharmaceuticals, Inc. presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, with a transcript of the presentation made available. No specific details from the presentation are included in the text.

Why it matters — INO watchers would care because the transcript offers management's recent remarks at a major healthcare investor conference.

Bet on 5 Top-Ranked Stocks With Rising P/E

Zacks Investment Research · 3 Sept 2026positive

Zacks Investment Research highlighted INO among five top-ranked stocks (CURI, INO, GDS, NMG, CCOI) that have increasing P/E ratios, presenting them as candidates for an unconventional investing approach.

Why it matters — INO watchers would note that the company was singled out by Zacks as a top-ranked stock with a rising P/E ratio, a sign it is attracting analytical attention.

FAQ

Frequently asked questions about INO stock

What is the INO stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Inovio Pharmaceuticals, Inc. have a median 12-month price target of $3, with estimates ranging from $2.5 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INO stock a buy right now?

Of the 3 analysts covering Inovio Pharmaceuticals, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inovio Pharmaceuticals, Inc. 42 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INO?

As at 12 Sept 2026, Inovio Pharmaceuticals, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).

Will INO stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +140.0% from the last close, and Ticker Nerd's factor model ranks Inovio Pharmaceuticals, Inc. 42 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INO stock forecast for 2030?

No analyst covering Inovio Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $4 over the next 12 months.

How has INO stock performed over the past year?

Inovio Pharmaceuticals, Inc. returned -52.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Inovio Pharmaceuticals, Inc. do?

Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases.

What is the latest news on INO?

The most recent item we track (Seeking Alpha, 11 Sept 2026): "Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript". Inovio Pharmaceuticals presented prepared remarks at the H.C. Wainwright 28th Annual Global Investment Conference. A transcript of these remarks has been published on Seeking Alpha.

Company

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company’s work centers on DNA-based immunotherapies and vaccines designed to help prevent or treat conditions such as recurrent respiratory papillomatosis, cervical dysplasia, and other virus-associated or oncology indications. Its platform combines synthetic DNA design with proprietary delivery technology to support immune-system activation across a range of therapeutic areas. Inovio’s current product pipeline reflects an emphasis on diseases linked to human papillomavirus as well as selected infectious and cancer-related programs. Based in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals Inc. occupies a specialized position in the biotechnology market as a developer of next-generation DNA medicine technologies.

CEO Dr. Jacqueline E. Shea Ph.D. · 112 employees · United States · https://www.inovio.com